OAM
VKTX icon

Oppenheimer Asset Management’s Viking Therapeutics VKTX Stock Holding History

Oppenheimer Asset Management’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-14,614
Closed -$92K – 1262
2021
Q3 		$92K Sell
14,614
-298
-2% -$1.84K ﹤0.01% 1180
2021
Q2 		$89K Sell
14,912
-163
-1% -$968 ﹤0.01% 1192
2021
Q1 		$95K Sell
15,075
-432
-3% -$3.04K ﹤0.01% 1145
2020
Q4 		$87K Sell
15,507
-253
-2% -$1.53K ﹤0.01% 1117
2020
Q3 		$92K Sell
15,760
-520
-3% -$3.58K ﹤0.01% 1068
2020
Q2 		$117K Buy
16,280
+273
+2% +$1.81K ﹤0.01% 1039
2020
Q1 		$75K Sell
16,007
-288
-2% -$1.77K ﹤0.01% 1176
2019
Q4 		$131K Sell
16,295
-412
-2% -$3K ﹤0.01% 1151
2019
Q3 		$115K Sell
16,707
-278
-2% -$2.06K ﹤0.01% 1157
2019
Q2 		$141K Sell
16,985
-2,684
-14% -$22.9K ﹤0.01% 1140
2019
Q1 		$196K Sell
19,669
-6,958
-26% -$58.2K ﹤0.01% 1044
2018
Q4 		$204K Buy
+26,627
New +$318K 0.01% 1000

Other funds holding VKTX

ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.47B AUM 86.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Oppenheimer Asset Management's VKTX Position: Q4 2021 in Review

Oppenheimer Asset Management sold out of Viking Therapeutics (VKTX) in Q4 2021, closing a stake of 14,614 shares — an estimated $92K sold.

Oppenheimer Asset Management first reported a position in VKTX in Q4 2018 and held it in 12 quarters. The position peaked at $204K in Q4 2018. 140 funds tracked by Wall St. Rank hold VKTX as of Q4 2021.

  • Oppenheimer Asset Management reported no remaining Viking Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Oppenheimer Asset Management sold 14,614 Viking Therapeutics shares in Q4 2021, an estimated $92K.
  • Oppenheimer Asset Management first reported a position in Viking Therapeutics in Q4 2018 and held it in 12 quarters.
  • Oppenheimer Asset Management's Viking Therapeutics position peaked at $204K in Q4 2018.
  • 140 funds tracked by Wall St. Rank held Viking Therapeutics as of Q4 2021.

Based on Oppenheimer Asset Management's 13F filing for Q4 2021, filed 2 Feb 2022.